Pfizer predicts a $15B avalanche of cash from its Covid-19 vaccine in 2021 as the R&D team claims a big spike in the trial success rate
If anyone wants a lesson in the value of being first-in-class and best-in-class in the drug business, pick up a copy of Pfizer’s quarterly report today.
The pharma giant, long considered a lumbering behemoth in R&D, picked up a radical new mRNA vaccine from BioNTech for Covid-19 and just spiked the ball in the commercial end zone — all inside of a year. And they’ve already lined up enough contracts to back a pledge that this vaccine will bring in a total of $15 billion in 2021 alone — half of which they can keep.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.